Oestrogel (estradiol-17β) Pump-Pack

  • Individualisation of treatment: The only oestrogen gel available in a Pump-Pack enabling dose tailoring (from 2 to 4 pump actuations a day) compared to fixed dose combined HRT preparations1,2
  • Frequency of administration: Daily administration of a colourless gel 1
  • Patient support available: Request your ‘How to use Oestrogel guide’ for patients now
  • Cost: £4.20 NHS price for 28 days treatment at a starting dose of 2 pumps daily 2 (based on £4.80 for 80g pump pack)

Active ingredient

Oestrogel is a transdermal gel containing 17β – oestradiol (administered at a standard dose of 1.5 mg daily), which is chemically and biologically identical to endogenous human oestradiol, and is used for menopausal oestrogen depletion.

Indications 1

  • HRT for oestrogen deficiency symptoms in post-menopausal women
  • Prevention of osteoporosis in post-menopausal women at high risk of fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of osteoporosis

Oestrogel reduces vasomotor symptoms and alleviates vaginal atrophy associated with menopause 3,4

In a double-blind, randomised, placebo controlled phase 3 study over 12 weeks: Oestrogel Pump-Pack significantly reduced the mean daily frequency (see Figure 1) and severity (see Figure 2) of hot flushes (p=0.05), compared to placebo: 3,4

Dosing schedule1

    • Each metered dose or pump actuation from the Pump-Pack is 1.25 g of Oestrogel, which contains 0.75 mg 17β – oestradiol. The normal daily starting dose is two metered doses: 2.5 g, which together contain 1.5 mg 17β – oestradiol. This will provide effective relief for most women, but the dose can easily be tailored if necessary, up to a maximum of four metered doses ( 5 g gel; 3 mg 17β – oestradiol)1
    • The patient should apply the gel to a large area (at least 750cm2) of clean, dry skin on the arms, shoulders or mid-inner thighs.  Oestrogel should NOT be applied on or near the breasts or on the vulval region. A frequent change in application sites is recommended1

.

Patient support

Dedicated website and leaflet available to inform patients about their treatment, improve their understanding of the menopause and aid compliance

  • Information on the menopause and HRT
  • Visual explanations on how to use Oestrogel Pump Pack
  • Downloadable diary to record symptoms to enable discussion with their healthcare professional

References

1. Besins Healthcare (UK) Ltd; EMC. Oestrogel Pump-Pack. Summary of Product Characteristics (last updated July 2019) Available from: www.medicines.org.uk/emc/product/353/smpc [accessed July 2019].
2. Data on file, BHUK/2018/270 – Based on MIMS online HRT table
3. Archer DF. Percutaneous 17β-estradiol gel for the treatment of vasomotor symptoms in postmenopausal women. Menopause 2003;10(6):516-521
4. Archer DF et al. Transdermal estradiol gel for the treatment of symptomatic postmenopausal women. Menopause 2012; 19(6): 622-629.

Menu
Complete the survey